Quarterly Result13 May 2025, 02:28 pm
Cipla Q4 & FY25 Results: Operational Excellence Driving 8% YoY Growth
AI Summary
Cipla Limited, a leading global pharmaceutical company, announced its audited consolidated financial results for the quarter ended March 31, 2025. The company recorded a revenue growth of 8% YoY, driven by operational efficiencies. The One-India business grew at a healthy 7% YoY, with key therapies in Branded Prescription business outpacing the market growth. The US business posted an all-time high annual revenue of $ 934 Mn. One Africa recorded a solid growth of 12% YoY in USD terms, and Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY in USD terms.
Key Highlights
- Revenue growth of 8% YoY with EBITDA margin of 25.9%
- One-India business grew at a healthy 7% YoY
- US business posted an all-time high annual revenue of $ 934 Mn
- One Africa recorded a solid growth of 12% YoY in USD terms
- Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY in USD terms